Get started
Author

Amy Templeman

Observed name: Templeman, Amy
ORCID: 0009-0007-9797-0773
Observed ORCID: 0009-0007-9797-0773
OpenAlex ID: A5059756276
Analytical performance of the FDA-cleared Parsortix® PC1 system
2023 · Amy Templeman, M. Craig Miller, et al. · Journal of Circulating Biomarkers · 38
PDF
TBX2 acts as a potent transcriptional silencer of tumour suppressor genes through interaction with the CoREST complex to sustain the proliferation of breast cancers
2022 · Alexander J McIntyre, Charlotte Z Angel, et al. · Nucleic Acids Research · 24
PDF
Development of a potent and selective cell penetrant Legumain inhibitor
2015 · Kerry A. Ness, Sharon L. Eddie, et al. · Bioorganic & Medicinal Chemistry Letters · 21
Molecular Profiling of Circulating Tumour Cells and Circulating Tumour DNA: Complementary Insights from a Single Blood Sample Utilising the Parsortix® System
2024 · Gabrielle Wishart, Amy Templeman, et al. · Current Issues in Molecular Biology · 14
PDF
P3 SAR exploration of biphenyl carbamate based Legumain inhibitors
2014 · Catherine Higgins, Samira Bouazzaoui, et al. · Bioorganic & Medicinal Chemistry Letters · 14
Abstract 4880: Parsortix™ system: Analytic performance evaluation using ovarian cancer cell lines
2019 · Arianna Hustler, Gabrielle Wishart, et al. · Cancer Research · 1
Elevating the Social Determinants of Health with a Focus on Achieving Health Equity
2023 · Levison-Johnson, Jody, Templeman, Amy · Social Innovations Journal
PDF
Abstract 4880: Parsortix™ system: Analytic performance evaluation using ovarian cancer cell lines
2019 · Arianna Hustler, Gabrielle Wishart, et al. · Clinical Research (Excluding Clinical Trials)
Works count: 9
Citation count: 112
H-index: 5
I10-index: 5
Year
Topic
Type